MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

Returns on capital

MBX Biosciences, Inc. Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-23.6%

avg 14.7%

ROIC

-26.5%

avg -39.3%

ROA

-22.6%

avg -35.6%

Analysis

ROA is currently the strongest return metric at -22.6% versus its period average of -35.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Salomon Azoulay

Chief Medical OfficerUSD 734.94K6814.03K0.04%

John W. Smither

Chief Financial OfficerUSD 642K7328.00K0.08%

Steven L. Hoerter

Executive Chairperson, CEO & PresidentUSD 40.48K5578.05K0.23%

Jeffrey Held

Chief Legal Officer—57——

Mark Hope

Chief Regulatory & Quality Officer————

Andreas Moraitis

Senior Vice President of Clinical Development————

Mark R. Soued

Chief Commercial Officer————

Karen Basbaum

Chief Business Officer————

Michelle Graham

Chief Human Resources Officer—59——

Pete De Spain

Senior Vice President of Investor Relations & Corporate Communications————

Chatan Charan

Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls————

Michael A. Dorato DABT

Sr. Vice President of Discovery & Non-Clinical Development————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$525,662.70

Sells

7

$3.02M

Net Transaction Value

−$2.50M

Net selling

Most Active

Azoulay Salomon

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 10, 26

Hoerter Steven L.

Direct

Sell$268.2K
Nov 4, 26

Azoulay Salomon

Direct

Sell$20.1K
Aug 4, 26

Azoulay Salomon

Direct

Sell$24.3K
May 8, 26

Azoulay Salomon

Direct

Sell$2.1M
May 8, 26

Azoulay Salomon

Direct

Sell$574.6K
May 6, 26

Hawryluk P. Kent

Direct

Sell$17.9K
May 6, 26

Azoulay Salomon

Direct

Sell$6.8K
Mar 13, 26

Hawryluk P. Kent

Indirect

Buy$525.7K

Summary

Insiders reported 1 buys worth $525,662.70 and 7 sells worth $3.02M over the last 12 months. That adds up to net selling of $2.50M. Azoulay Salomon was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does MBX Biosciences, Inc. Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MBX's management, answered from reported figures.

Who manages MBX?

MBX Biosciences, Inc. Common Stock (MBX) lists 12 active executives. The top listed executive is Jeffrey Held, Chief Legal Officer.

Are MBX insiders buying or selling?

Recent insider activity shows net buying of $215.80M.